COVID-19 vaccine safety checked in cancer immunotherapy patients

NCT ID NCT05025514

Terminated Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if COVID-19 vaccines cause more side effects in cancer patients receiving immunotherapy. Researchers planned to track 125 patients from several hospitals in France, recording any local or systemic side effects. The study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COVID-19 vaccines (BNT162b2, mRNA-1273, Oxford/AstraZeneca, Ad26COV2.S)
What this could lead to: If successful, this could show that COVID-19 vaccines are safe for cancer patients on immunotherapy, helping guide vaccination recommendations.
What could go wrong: The study was terminated early with only 125 participants, so results may be incomplete. It was also observational, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer COVID-19 neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER IMMUNOTHERAPY

Contacts and locations

Locations

CH d'Auch

Auch, 32008, France
CH de Cahors

Cahors, France
CHU de Nîmes

Nîmes, Gard, 30029, France
Centre Hospitalier d'Albi

Albi, France
Clinique des Cèdres - Capio

Cornebarrieu, 31700, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.